Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

Editorial

Preface

John T. Isaacs Ph.D.,  William W. Scott M.D., 
  • Pages: 223-225
  • First Published: 05 May 1999

Modulation of the differentiation status of cultured prostatic smooth muscle cells by an α1-adrenergic receptor antagonist

Simone T. Boesch,  Stefan Corvin,  Ju Zhang,  Hermann Rogatsch,  Georg Bartsch,  Helmut Klocker, 
  • Pages: 226-233
  • First Published: 05 May 1999

Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359†

Michael K. Brawer,  Daniel W. Lin,  William O. Williford,  Karen Jones,  Herbert Lepor, 
  • Pages: 234-239
  • First Published: 05 May 1999

Unique morphological aspects of the rat ventral prostate gland revealed by vascular corrosion casting

Ahmad Shabsigh,  Benjamin Lee,  Ralph Buttyan, 
  • Pages: 240-245
  • First Published: 05 May 1999
Free Access

Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

Kenneth S. Koeneman,  Fan Yeung,  Leland W.K. Chung, 
  • Pages: 246-261
  • First Published: 05 May 1999

Links between genetic and environmental factors and prostate cancer risk

Peter Ekman,  Henrik Grönberg,  Hideyasu Matsuyama,  Merja Kivineva,  Ulf S.R. Bergerheim,  Chunde Li, 
  • Pages: 262-268
  • First Published: 05 May 1999

Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells

Samuel R. Denmeade,  Xiaohui S. Lin,  Bertrand Tombal,  John T. Isaacs, 
  • Pages: 269-279
  • First Published: 05 May 1999

No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer

Eric P. Wilkens,  Diha Freije,  Jianfeng Xu,  Deborah R. Nusskern,  Hiroyoshi Suzuki,  Sarah D. Isaacs,  Kathleen Wiley,  Piroska Bujnovszky,  Deborah A. Meyers,  Patrick C. Walsh,  William B. Isaacs, 
  • Pages: 280-284
  • First Published: 05 May 1999

Transforming growth factor-β in benign and malignant prostate

Chung Lee,  Sharon M. Sintich,  Eric P. Mathews,  Ali H. Shah,  Shilajit D. Kundu,  Kent T. Perry,  Jin Seon Cho,  Kenneth Y. Ilio,  Marcus V. Cronauer,  Lynn Janulis,  Julia A. Sensibar, 
  • Pages: 285-290
  • First Published: 05 May 1999

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial†

S.J. Simmons,  B.A. Tjoa,  M. Rogers,  A. Elgamal,  G.M. Kenny,  H. Ragde,  M.J. Troychak,  A.L. Boynton,  G.P. Murphy, 
  • Pages: 291-297
  • First Published: 05 May 1999

Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23

Eric N.P. Subong,  Matthew J. Shue,  Jonathan I. Epstein,  Joseph V. Briggman,  Pui K. Chan,  Alan W. Partin, 
  • Pages: 298-304
  • First Published: 05 May 1999

Prevention of prostate-related cancers in Lobund-Wistar rats

Morris Pollard, 
  • Pages: 305-309
  • First Published: 05 May 1999

Origin and racial distribution of glandular tissue in the anterior compartment of the prostate: An autopsy study

Rabi Tiguert,  Wareef Kabbani,  Wael Sakr,  Edward L. Gheiler,  J. Edson Pontes, 
  • Pages: 310-315
  • First Published: 05 May 1999

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)

Ries Kranse,  Petra Beemsterboer,  John Rietbergen,  Dik Habbema,  Jonas Hugosson,  Fritz H. Schröder, 
  • Pages: 316-322
  • First Published: 05 May 1999

The Real Final Exam

Donald S. Coffey, 
  • Pages: 323-325
  • First Published: 05 May 1999